Ginkgo Bioworks Holdings Inc (NYSE: DNA) stock jumped 4.11% on Friday to $1.52 against a previous-day closing price of $1.46. With 12.22 million shares changed hands, the volume of the stock remained lighter than its average volume of 19.92 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.5200 whereas the lowest price it dropped to was $1.4300. The 52-week range on DNA shows that it touched its highest point at $2.55 and its lowest point at $1.12 during that stretch. It currently has a 1-year price target of $3.38. Beta for the stock currently stands at 1.33.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DNA was up-trending over the past week, with a rise of 18.75%, but this was down by -2.56% over a month. Three-month performance dropped to -8.43% while six-month performance rose 18.75%. The stock lost -34.48% in the past year, while it has lost -10.06% so far this year. A look at the trailing 12-month EPS for DNA yields -0.45 with Next year EPS estimates of -0.28. For the next quarter, that number is -0.10. This implies an EPS growth rate of 66.70% for this year and 31.53% for next year.
Float and Shares Shorts:
At present, 1.34 billion DNA shares are outstanding with a float of 1.30 billion shares on hand for trading. On Oct 30, 2023, short shares totaled 235.94 million, which was 11.14% higher than short shares on Sep 28, 2023. In addition to Dr. Jason Kelly as the firm’s Founder, CEO & Director, Dr. Reshma P. Shetty serves as its Founder, President, COO & Director.
Through their ownership of 80.98% of DNA’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 40.42% of DNA, in contrast to 31.48% held by mutual funds. Shares owned by individuals account for 2.71%. As the largest shareholder in DNA with 14.92% of the stake, Baillie Gifford & Co. holds 238,808,823 shares worth 238,808,823. A second-largest stockholder of DNA, ARK Investment Management LLC, holds 182,192,185 shares, controlling over 11.38% of the firm’s shares. Viking Global Investors LP is the third largest shareholder in DNA, holding 143,085,126 shares or 8.94% stake. With a 7.85% stake in DNA, the ARK Innovation ETF is the largest stakeholder. A total of 125,634,550 shares are owned by the mutual fund manager. The Scottish Mortgage Investment Trus, which owns about 5.98% of DNA stock, is the second-largest Mutual Fund holder. It holds 95,665,963 shares valued at 131.06 million. ARK Genomic Revolution ETF holds 3.30% of the stake in DNA, owning 52,782,252 shares worth 72.31 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DNA since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DNA analysts setting a high price target of $7.00 and a low target of $1.25, the average target price over the next 12 months is $3.38. Based on these targets, DNA could surge 360.53% to reach the target high and fall by -17.76% to reach the target low. Reaching the average price target will result in a growth of 122.37% from current levels.
Summary of Insider Activity:
Insiders traded DNA stock several times over the past three months with 6 Buys and 45 Sells. In these transactions, 170,088 shares were bought while 2,446,852 shares were sold. The number of buy transactions has increased to 45 while that of sell transactions has risen to 370 over the past year. The total number of shares bought during that period was 1,707,085 while 33,821,112 shares were sold.